Literature DB >> 22855545

Favorable effect of sorafenib in a patient with neurofibromatosis-associated pulmonary hypertension.

Yuichi Tamura, Tomohiko Ono, Motoaki Sano, Keiichi Fukuda, Masaharu Kataoka, Toru Satoh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22855545     DOI： 10.1164/ajrccm.186.3.291

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  4 in total

1.  Atrial septostomy and disease targeting therapy in pulmonary hypertension secondary to neurofibromatosis.

Authors:  George Giannakoulas; Panagiotis Savvoulidis; Vasilios Grosomanidis; Sophia-Anastasia Mouratoglou; Haralambos Karvounis; Stavros Hadjimiltiades
Journal:  BMC Pulm Med       Date:  2016-12-07       Impact factor: 3.317

2.  Severe dyspnea in a patient with neurofibromatosis type 1.

Authors:  P B Poble; J C Dalphin; B Degano
Journal:  Respir Med Case Rep       Date:  2017-06-17

Review 3.  Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension.

Authors:  Mazen Al-Qadi; Barbara LeVarge; H James Ford
Journal:  Front Med (Lausanne)       Date:  2021-03-25

4.  An Uncommon Incidence of Pulmonary Hypertension Associated With Neurofibromatosis Type 1: A Case Report.

Authors:  Suman Rao; Alisha Khan; Parth Sampat; Michael Sandhu; Andrew M Weinberg
Journal:  J Investig Med High Impact Case Rep       Date:  2021 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.